| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 08/07/2013 | CN101745102B Composition of 5-aminolevulinic acid and derivative thereof as well as application thereof |
| 08/07/2013 | CN101703490B Polysaccharide/inorganic nanoparticles hybrid micron-nano medicine-carrying capsule |
| 08/07/2013 | CN101460198B Thermosensitive polyphosphazene-bioactive molecule conjugates, preparation method thereof and use thereof |
| 08/07/2013 | CN101450215B Polylactic acid-glycolic acid co-polymer nanometer granule with immunotoxin out-connection antibody inside |
| 08/07/2013 | CN101312989B Monoclonal antibodies against claudin-18 for treatment of cancer |
| 08/07/2013 | CN101267806B Sustained release of antifectives |
| 08/07/2013 | CN101080222B Chemically stable compositions of 4-hydroxy tamoxifen |
| 08/06/2013 | US8501906 Compounds and methods for treating cancer |
| 08/06/2013 | US8501824 Amino acid lipids and uses thereof |
| 08/06/2013 | US8501823 Oil-in-water emulsion cosmetic composition and method for producing the same |
| 08/06/2013 | US8501822 Ophthalmic composition containing alginic acid or salt thereof |
| 08/06/2013 | US8501799 Pharmaceutical composition containing an N-phenylpyrazole derivative, and use thereof for preparing a topical veterinary for flea control |
| 08/06/2013 | US8501697 Peptide nanostructures encapsulating a foreign material and method of manufacturing same |
| 08/06/2013 | US8501240 Compositions comprising an active agent |
| 08/06/2013 | US8501236 Method for producing a crystalline tableting additive, additive thus obtained and use thereof |
| 08/06/2013 | US8501231 Pharmaceutical compositions providing enhanced drug concentrations |
| 08/06/2013 | US8501221 Methods for preparing and delivering adjuvant compositions |
| 08/06/2013 | US8501220 Stabilized liquid egg material for extended shelf life |
| 08/06/2013 | US8501219 Flavoring systems for pharmaceutical compositions and methods of making such compositions |
| 08/06/2013 | US8501218 Edible chew pill jacket |
| 08/06/2013 | US8501216 Bioerodible polymers for injection |
| 08/06/2013 | US8501215 Having a solvent with a miscibility in water of less than or equal to 7 wt. % at 25 degrees C., to plasticize the polymer and form a gel therewith; improved shear thinning behavior and reduced injection force |
| 08/06/2013 | US8501196 Pharmaceutical compositions containing botulinum neurotoxin |
| 08/06/2013 | US8501165 Biocompatible tissue-bonding adhesive composition comprising an isocyanate-capped polyether, especially a ethylene oxide-propylene oxide polymer |
| 08/06/2013 | US8501158 Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents |
| 08/06/2013 | CA2732620C Crystalline form of 40-o-(2-hydroxy-ethyl) rapamycin and process for preparation thereof |
| 08/06/2013 | CA2728939C Heparin-conjugated fibrin gel and method and kit for preparing the same |
| 08/06/2013 | CA2723119C Pharmaceutical compound comprising a strontium salt, vitamin d and a cyclodextrin |
| 08/06/2013 | CA2714081C Methods and compositions for treating conditions of the eye |
| 08/06/2013 | CA2703000C Water-immiscible materials as vehicles for drug delivery |
| 08/06/2013 | CA2689696C Microemulsions with adsorbed macromolecules and microparticles |
| 08/06/2013 | CA2672907C Pegylated pth as pth receptor modulators and uses thereof |
| 08/06/2013 | CA2650626C Delivery of active agents using a chocolate vehicle |
| 08/06/2013 | CA2619278C Method for encapsulating therapeutic substances in cells |
| 08/06/2013 | CA2577690C Refolding transforming growth factor beta family proteins |
| 08/06/2013 | CA2556305C Rapidly dissolving solid oral dosage form for delivery of composition for increasing nitric oxide activity |
| 08/06/2013 | CA2522580C A medicament for the two-step perioperative therapy of solid tumours |
| 08/06/2013 | CA2521826C Recombinant il-9 antibodies and uses thereof |
| 08/06/2013 | CA2451839C Pharmaceutical compositions comprising peptides and permeation enhancers |
| 08/06/2013 | CA2425779C Compositions that inhibit proliferation of cancer cells |
| 08/06/2013 | CA2368213C Specifically targeted catalytic antagonists and uses thereof |
| 08/01/2013 | WO2013112491A1 Tunable hydrogel materials and methods for preparing the same |
| 08/01/2013 | WO2013112488A2 Dermal filling compositions and methods |
| 08/01/2013 | WO2013112456A1 Controlled release formulations for the induction and proliferation of blood cells |
| 08/01/2013 | WO2013112438A1 Stabilized formulations containing anti-ang2 antibodies |
| 08/01/2013 | WO2013112212A2 Metal-organic frameworks with exceptionally large pore aperatures |
| 08/01/2013 | WO2013111817A1 Oil-in-water-type creamy composition containing tacrolimus |
| 08/01/2013 | WO2013111759A1 Collagen-like peptide having stealth property and high urinary excretion property |
| 08/01/2013 | WO2013111012A2 Methods and compositions for therapeutic agents |
| 08/01/2013 | WO2013110856A1 A drug delivery system |
| 08/01/2013 | WO2013110830A1 Pharmaceutical composition comprising isometamidium chloride in solution for the treatment of trypanosomiasis in animals |
| 08/01/2013 | WO2013110809A1 Edible slow dissolving film for treating oral ulcerations |
| 08/01/2013 | WO2013110681A1 Chitosan covalently linked with small molecule integrin antagonist for targeted delivery |
| 08/01/2013 | WO2013110680A1 Integrin antagonist conjugates for targeted delivery to cells expressing vla-4 |
| 08/01/2013 | WO2013110679A1 Integrin antagonist conjugates for targeted delivery to cells expressing lfa-1 |
| 08/01/2013 | WO2013110644A1 Pharmaceutical composition containing crystalline sorafenib tosylate |
| 08/01/2013 | WO2013110621A1 Stabilised protein compositions based on semifluorinated alkanes |
| 08/01/2013 | WO2013110578A1 Integrin antagonist conjugates for targeted delivery to cells expressing alpha-v-beta-3 |
| 08/01/2013 | WO2013110567A1 Novel orally administered dabigatran formulation |
| 08/01/2013 | WO2013110471A1 Means for endotoxin detoxification |
| 08/01/2013 | WO2013055058A3 Antibody-binding peptide-ferritin fusion protein and uses thereof |
| 08/01/2013 | WO2013048222A3 Peptide for synthesizing silica, and use thereof |
| 08/01/2013 | WO2013012961A3 Sugar alcohol-based crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof |
| 08/01/2013 | WO2012085668A3 Compounds |
| 08/01/2013 | WO2011163594A3 Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
| 08/01/2013 | US20130197359 Solid lipid nanoparticles including elastin-like polypeptides and use thereof |
| 08/01/2013 | US20130197210 Complexing agents for compositions containing inclusion complexes |
| 08/01/2013 | US20130197205 Chitosan covalently linked with small molecule integrin antagonist for targeted delivery |
| 08/01/2013 | US20130197203 Modified Polysaccharides for Conjugate Vaccines |
| 08/01/2013 | US20130197105 Dpi formulation containing sulfoalkyl ether cyclodextrin |
| 08/01/2013 | US20130197103 Composition and method for the enhancement of the efficacy of drugs |
| 08/01/2013 | US20130197101 Novel electrolyte-resistant cationic thickeners usable over a wide ph range, method for preparing same, and composition containing same |
| 08/01/2013 | US20130197093 Enhanced bimatoprost ophthalmic solution |
| 08/01/2013 | US20130197092 Novel Non-Aqueous Topical Solution of Diclofenac and Process for Preparing the Same |
| 08/01/2013 | US20130197083 Efficient lipid delivery to human tear film using a salt-sensitive emulsion system |
| 08/01/2013 | US20130197035 Surgical Adjuvant Composition and Associated Methods of Use |
| 08/01/2013 | US20130196995 Combination of brimonidine and timolol for topical ophthalmic use |
| 08/01/2013 | US20130196963 Topical steroidal formulations |
| 08/01/2013 | US20130196957 Roll-on with high salicylic acid content |
| 08/01/2013 | US20130196946 Cyclodextrin-based polymers for therapeutic delivery |
| 08/01/2013 | US20130196945 Cyclodextrin-based polymers for therapeutics delivery |
| 08/01/2013 | US20130196926 Controlled release of ocular biopharmaceuticals using bioresponsive protein polymers |
| 08/01/2013 | US20130196915 Affinity hydrogels for controlled protein release |
| 08/01/2013 | US20130196906 Cyclodextrin-based polymers for therapeutic delivery |
| 08/01/2013 | US20130196903 Multimeric Inhibitors of Viral Fusion and Uses Thereof |
| 08/01/2013 | US20130196897 Glucosamine Pro-drug |
| 08/01/2013 | US20130196003 Class of anti-adhesion hydrogels with healing aspects |
| 08/01/2013 | US20130195987 Polymeric micelles for drug delivery |
| 08/01/2013 | US20130195986 New Particles of Tetracyclines and Protecting Agent |
| 08/01/2013 | US20130195975 In vivo use of water absorbent polymers |
| 08/01/2013 | US20130195974 Ph-dependent gradual release pharmaceutical composition |
| 08/01/2013 | US20130195971 Pharmaceutical composition 271 |
| 08/01/2013 | US20130195954 Films and particles |
| 08/01/2013 | US20130195941 Pullulan-containing powder, method for producing the same and use thereof |
| 08/01/2013 | US20130195935 Abuse-proofed dosage form |
| 08/01/2013 | US20130195932 Archaeal polar lipid aggregates for administration to animals |
| 08/01/2013 | US20130195929 Active ingredient delivery system with an amorphous metal salt as carrier |
| 08/01/2013 | US20130195924 Water-soluble pharmaceutical composition comprising at least one therapeutically active substance having hydrophobic properties and at least one compound selected from among sialoglycosphingolipids, glycosphingolipids or a mixture of sialoglycosphingolipids and glycosphingolipids |
| 08/01/2013 | US20130195921 Methods for regulating gelation of hydrogel solutions and uses thereof |
| 08/01/2013 | US20130195920 Biodegradable lipids for the delivery of active agents |